Molbio Diagnostics IPO has opened for public subscription today, August 10, 2026, giving investors an opportunity to participate in the initial public offering of one of India’s prominent point-of-care molecular diagnostics companies. The IPO will remain open until August 12, 2026.
The company has fixed the IPO price band at ₹768 to ₹807 per equity share. With strong interest from investors and positive grey-market indications, the Molbio Diagnostics IPO is expected to remain in focus throughout the subscription period.
Molbio Diagnostics IPO
| Particular | Details |
|---|---|
| Company Name | Molbio Diagnostics Limited |
| IPO Name | Molbio Diagnostics IPO |
| IPO Type | Mainboard IPO |
| IPO Opening Date | August 10, 2026 |
| IPO Closing Date | August 12, 2026 |
| Price Band | ₹768 – ₹807 per share |
| Face Value | ₹1 per share |
| Issue Size | Approx. ₹939.7 crore |
| Fresh Issue | Approx. ₹200 crore |
| Offer for Sale | Approx. ₹739.7 crore |
| Lot Size | 18 shares |
| Minimum Investment | ₹14,526 |
| Listing | NSE and BSE |
| Business | Molecular and point-of-care diagnostics |
The total issue size is approximately ₹939.7 crore, comprising a fresh issue of around ₹200 crore and an offer for sale of approximately ₹739.7 crore.
Molbio Diagnostics IPO GMP Today
The Molbio Diagnostics IPO GMP has attracted considerable attention ahead of the issue opening. Recent reports indicated a grey-market premium of around ₹122 per share, although other market sources have reported different GMP levels as market conditions changed.
At a GMP of ₹122 and the upper price band of ₹807, the indicative grey-market price would be around ₹929, suggesting a potential premium of roughly 15% over the issue price. However, investors should remember that GMP is unofficial and can change rapidly. It should not be treated as a guaranteed listing gain or a recommendation to subscribe.
Molbio Diagnostics IPO Price Band
Molbio Diagnostics has fixed the price band at ₹768 to ₹807 per share. Retail investors can bid for a minimum of 18 shares, which means the minimum investment at the upper price band will be: 18 × ₹807 = ₹14,526. Investors can place bids within the specified price band during the IPO subscription period.
Molbio Diagnostics IPO Dates
The Molbio Diagnostics IPO opened on August 10, 2026, and the subscription window will close on August 12, 2026. Investors should complete their applications before the closing date if they wish to participate in the issue.
The allotment, refund/unblocking and share credit process will take place after the subscription period, followed by the company’s stock market listing.
About Molbio Diagnostics
Molbio Diagnostics is a medical technology company focused on point-of-care molecular diagnostics. The company is best known for its Truenat platform, which enables molecular diagnostic testing closer to the point of patient care.
Its products are designed to support rapid testing across healthcare settings, including areas where access to conventional laboratory infrastructure can be limited. The company’s business has also developed an international footprint, making global expansion an important part of its growth strategy.
Molbio Diagnostics Financial Performance
Molbio Diagnostics has reported strong growth in revenue and profitability over the last few financial years. According to IPO-related financial data, the company’s revenue increased from around ₹840.6 crore in FY2024 to approximately ₹1,028 crore in FY2025 and further to around ₹1,455 crore in FY2026.
Profit after tax also increased from approximately ₹83.5 crore in FY2024 to around ₹138.6 crore in FY2025, before reaching approximately ₹164.1 crore in FY2026. This improvement in revenue and profitability is one of the key factors attracting investor attention to the IPO.
Molbio Diagnostics IPO: Where Will the Money Be Used?
A portion of the fresh issue proceeds is intended to support the company’s business expansion and infrastructure requirements.
The company plans to invest in areas including research and development, manufacturing infrastructure and growth initiatives. The IPO documents indicate that funding research and infrastructure is an important part of the company’s plans.
The Molbio Diagnostics IPO has entered the primary market with a price band of ₹768–₹807 per share and an issue size of approximately ₹939.7 crore. The company’s strong financial growth, molecular diagnostics business and Truenat platform have made the IPO a key issue for investors to watch in August 2026.
Molbio Diagnostics Official Websites : Visit
Note: Molbio Diagnostics IPO GMP is based on unofficial grey-market activity and may change frequently. GMP should not be considered a guaranteed indication of the IPO listing price. Investors should check the latest official IPO documents, subscription data and company disclosures before making any investment decision. The information provided in this article is for educational and informational purposes only and should not be considered investment advice.
